Regression of Peripheral Subclinical Enthesopathy in Therapy ‐Naive Patients Treated With Ustekinumab for Moderate‐to‐Severe Chronic Plaque Psoriasis: A Fifty‐Two–Week, Prospective, Open‐Label Feasibility Study

ConclusionWithin 12 weeks of treatment, interleukin ‐12 (IL‐12)/IL‐23 inhibition for psoriasis appears to suppress subclinical enthesopathy, and the suppression is maintained through week 52. Further longitudinal studies are needed to determine whether therapy initiated for skin disease may prevent the development of PsA.

Source: Arthritis and Rheumatology - March 3, 2019 Category: Rheumatology Authors: Laura Savage, Mark Goodfield, Laura Horton, Abdulla Watad, Elizabeth Hensor, Paul Emery, Richard Wakefield, Miriam Wittmann, Dennis McGonagle Tags: Brief Report Source Type: research